NovoCure Limited is a medical instruments & supplies business based in the US. NovoCure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. NovoCure employs 1,023 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in NovoCure
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NVCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
NovoCure stock price (NASDAQ: NVCR)Use our graph to track the performance of NVCR stocks over time.
NovoCure shares at a glance
|Latest market close||$204.00|
|52-week range||$74.21 - $232.76|
|50-day moving average||$200.86|
|200-day moving average||$178.45|
|Wall St. target price||$192.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.10|
Buy NovoCure shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy NovoCure stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
NovoCure price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||10.78%|
|3 months (2021-04-30)||-0.05%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Is NovoCure under- or over-valued?
Valuing NovoCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NovoCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NovoCure's P/E ratio
NovoCure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1569x. In other words, NovoCure shares trade at around 1569x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NovoCure's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $42.3 million.
The EBITDA is a measure of a NovoCure's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$527.2 million|
|Operating margin TTM||6.47%|
|Gross profit TTM||$388.3 million|
|Return on assets TTM||2.72%|
|Return on equity TTM||3.82%|
|Market capitalisation||$16.9 billion|
TTM: trailing 12 months
Shorting NovoCure shares
There are currently 5.1 million NovoCure shares held short by investors – that's known as NovoCure's "short interest". This figure is 5.5% down from 5.4 million last month.
There are a few different ways that this level of interest in shorting NovoCure shares can be evaluated.
NovoCure's "short interest ratio" (SIR)
NovoCure's "short interest ratio" (SIR) is the quantity of NovoCure shares currently shorted divided by the average quantity of NovoCure shares traded daily (recently around 836580.42763158). NovoCure's SIR currently stands at 6.08. In other words for every 100,000 NovoCure shares traded daily on the market, roughly 6080 shares are currently held short.
However NovoCure's short interest can also be evaluated against the total number of NovoCure shares, or, against the total number of tradable NovoCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NovoCure's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NovoCure shares in existence, roughly 50 shares are currently held short) or 0.0576% of the tradable shares (for every 100,000 tradable NovoCure shares, roughly 58 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NovoCure.
Find out more about how you can short NovoCure stock.
NovoCure share dividends
We're not expecting NovoCure to pay a dividend over the next 12 months.
NovoCure share price volatility
Over the last 12 months, NovoCure's shares have ranged in value from as little as $74.21 up to $232.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NovoCure's is 1.0745. This would suggest that NovoCure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. .
NovoCure in the news
Here's Why Novocure Dipped 19% This Week
NovoCure Limited 2021 Q2 - Results - Earnings Call Presentation
Novocure price target lowered to $200 from $229 at Mizuho
Frequently asked questionsWhat percentage of NovoCure is owned by insiders or institutions?
Currently 13.402% of NovoCure shares are held by insiders and 89.055% by institutions. How many people work for NovoCure?
Latest data suggests 1,023 work at NovoCure. When does the fiscal year end for NovoCure?
NovoCure's fiscal year ends in December. Where is NovoCure based?
NovoCure's address is: No. 4 The Forum, Saint Helier, Jersey, JE2 4UF What is NovoCure's ISIN number?
NovoCure's international securities identification number is: JE00BYSS4X48 What is NovoCure's CUSIP number?
NovoCure's Committee on Uniform Securities Identification Procedures number is: G6674U108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert